Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

181. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. (Full text)

Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Recent evidence suggests that daily aspirin use decreases cancer risk, particularly for colorectal cancer, but evidence for alternate-day use is scant.To examine the association between long-term, alternate-day, low-dose aspirin and cancer in healthy women.Observational follow-up of a randomized trial.Female health professionals.39,876 women aged 45 years or older in the Women's Health (...) Study (ClinicalTrials.gov: NCT00000479), 33 682 of whom continued observational follow-up.100 mg of alternate-day aspirin or placebo through March 2004, with a median 10-year follow-up. Posttrial follow-up continued through March 2012.Cancer incidence.A total of 5071 cancer cases (including 2070 breast, 451 colorectal, and 431 lung cancer cases) and 1391 cancer deaths were confirmed. Over the entire follow-up, aspirin had no association with total (hazard ratio [HR], 0.97 [95% CI, 0.92 to 1.03]; P

2013 Annals of Internal Medicine PubMed

182. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. (PubMed)

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone.In a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned 5170 patients within 24 hours after the onset of minor ischemic stroke (...) or high-risk TIA to combination therapy with clopidogrel and aspirin (clopidogrel at an initial dose of 300 mg, followed by 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days) or to placebo plus aspirin (75 mg per day for 90 days). All participants received open-label aspirin at a clinician-determined dose of 75 to 300 mg on day 1. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis. Treatment

2013 NEJM

183. Aspirin use and risk of colorectal cancer according to BRAF mutation status. (Full text)

Aspirin use and risk of colorectal cancer according to BRAF mutation status. Aspirin use reduces the risk of colorectal carcinoma. Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase 2), suggesting that BRAF-mutant colonic cells might be less sensitive to the antitumor effects of aspirin than BRAF-wild-type neoplastic cells.To examine whether the association of aspirin intake with colorectal cancer risk differs (...) according to status of tumor BRAF oncogene mutation.We collected biennial questionnaire data on aspirin use and followed up participants in the Nurses' Health Study (from 1980) and the Health Professionals Follow-up Study (from 1986) until July 1, 2006, for cancer incidence and until January 1, 2012, for cancer mortality. Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute hazard ratios (HRs) for colorectal carcinoma incidence according

2013 JAMA PubMed

184. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. (Full text)

Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. The role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial.To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA.Multicenter randomized, controlled trial with a noninferiority design based on a minimal clinically important difference of 2.0 (...) randomly assigned to 28 days of dalteparin (n = 400) or aspirin (n = 386).Symptomatic VTE confirmed by objective testing (primary efficacy outcome) and bleeding.Five of 398 patients (1.3%) randomly assigned to dalteparin and 1 of 380 (0.3%) randomly assigned to aspirin had VTE (absolute difference, 1.0 percentage point [95% CI, -0.5 to 2.5 percentage points]). Aspirin was noninferior (P < 0.001) but not superior (P = 0.22) to dalteparin. Clinically significant bleeding occurred in 5 patients (1.3

2013 Annals of Internal Medicine PubMed

185. Effect of low-dose aspirin on functional outcome from cerebral vascular events in women (Full text)

Effect of low-dose aspirin on functional outcome from cerebral vascular events in women Although aspirin is effective in prevention of stroke, fewer studies have examined the impact of aspirin on stroke morbidity.The Women's Health Study is a completed randomized, placebo-controlled trial designed to test the effect of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer, which enrolled 39 876 women. We used multinomial logistic regression to evaluate (...) the relationship between randomized aspirin assignment and functional outcomes from stroke. Possible functional outcomes were neither stroke nor transient ischemic attack (TIA), modified Rankin scale (mRS) score 0 to 1, 2 to 3, and 4 to 6.After a mean of 9.9 years of follow-up, 460 confirmed strokes (366 ischemic, 90 hemorrhagic, and 4 unknown type) and 405 confirmed TIAs occurred. With regard to total and ischemic stroke, women who were randomized to aspirin had a nonsignificant decrease in risk of any

2013 EvidenceUpdates PubMed

186. Aspirin with or without an antiemetic for acute migraine headaches in adults. (Full text)

Aspirin with or without an antiemetic for acute migraine headaches in adults. This is an updated version of the original Cochrane review published in Issue 4, 2010 (Kirthi 2010). Migraine is a common, disabling condition and a burden for the individual, health services and society. Many sufferers choose not to, or are unable to, seek professional help and rely on over-the-counter analgesics. Co-therapy with an antiemetic should help to reduce nausea and vomiting commonly associated (...) with migraine headaches.To determine the efficacy and tolerability of aspirin, alone or in combination with an antiemetic, compared to placebo and other active interventions in the treatment of acute migraine headaches in adults.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the Oxford Pain Relief Database, ClinicalTrials.gov, and reference lists for studies through 10 March 2010 for the original review and to 31 January 2013 for the update.We included randomised

2013 Cochrane PubMed

187. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. (PubMed)

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding. We investigated the safety and efficacy of clopidogrel alone compared with clopidogrel (...) plus aspirin.We did an open-label, multicentre, randomised, controlled trial in 15 centres in Belgium and the Netherlands. From November, 2008, to November, 2011, adults receiving oral anticoagulants and undergoing PCI were assigned clopidogrel alone (double therapy) or clopidogrel plus aspirin (triple therapy). The primary outcome was any bleeding episode within 1 year of PCI, assessed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00769938.573 patients were

2013 Lancet

188. Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. (PubMed)

Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. 23552619 2013 05 13 2013 04 04 1539-3704 158 6 2013 Mar 19 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. JC2 10.7326/0003-4819-158-6-201303190-02002 Deloughery Thomas T eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 N Engl J Med. 2012 Nov 22;367(21):1979-87 23121403 2013 4 5

2013 Annals of Internal Medicine

189. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable

Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of clopidogrel plus aspirin, compared with aspirin alone, for the prevention of stroke in patients with uncomplicated atrial fibrillation. The authors concluded

2013 NHS Economic Evaluation Database.

190. WARFASA: Aspirin for Preventing the Recurrence of Venous Thromboembolism

WARFASA: Aspirin for Preventing the Recurrence of Venous Thromboembolism RXFILES TRIAL SUMMARY MATTHEW SWANKHUIZEN – MAY 2013 – WWW.RXFILES.CA Page 1 of 2 WARFASA: Aspirin for Preventing the Recurrence of Venous Thromboembolism 1 WARFarin and AcetylSalicylic Acid Study BOTTOM LINE • In patients whom have had a first unprovoked VTE with low to moderate bleed risk, the addition of ASA 100 mg daily is reasonable to prevent future DVT not PE or mortality events, if the decision is made to stop VKA (...) Prevention >45,no history of CHD,CVD, cancer or other major diseases. 4 • Prior to the WARFASA trial there was no evidence looking at secondary prevention of VTE in patients who have discontinued warfarin. The aim of the WARFASA study was to assess the clinical benefit of aspirin for the prevention of recurrence after a course of treatment with VKA in patients with unprovoked venous thromboembolism. TRIAL BACKGROUND 1,5,6,7,8 DESIGN: Randomized Allocation Concealed , multi-centre 25 sites in European

2013 RxFiles

191. ASPIRE: Low?Dose Aspirin for Preventing Recurrent Venous Thromboembolism

ASPIRE: Low?Dose Aspirin for Preventing Recurrent Venous Thromboembolism RXFILES TRIAL SUMMARY MATTHEW SWANKHUIZEN – MAY 2013 – WWW.RXFILES.CA Page 1 of 2 ASPIRE: Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism 1 Aspirin to Prevent Recurrent Venous Thromboembolism BOTTOM LINE • In patients whom have had an unprovoked VTE with low to moderate bleed risk the addition of ASA 100 mg daily is reasonable to prevent future VTE events and major vascular events if the decision is made (...) with a VKA for unprovoked VTE, starting ASA 100 mg daily once the VKA was stopped resulted in a significant reduction in future VTE events . 2 See RxFiles Trial Summary http://www.rxfiles.ca/rxfiles/uploads/documents/Aspirin-warfarin-trial-summary-WarfASA.pdf • The objective of the ASPIRE study was to add to current literature and evaluate the efficacy of low-dose aspirin as compared to placebo , in preventing a recurrence of VTE in patients who had completed initial anticoagulation after a first

2013 RxFiles

192. Cohort study: Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people with diabetes who have a high baseline rate of bleeding

Cohort study: Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people with diabetes who have a high baseline rate of bleeding Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people with diabetes who have a high baseline rate of bleeding | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people

2013 Evidence-Based Nursing

193. Systematic review with meta-analysis: Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality

Systematic review with meta-analysis: Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin prophylaxis in people without prior cardiovascular disease does

2013 Evidence-Based Medicine (Requires free registration)

194. Randomised controlled trial: Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes

Randomised controlled trial: Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar

2013 Evidence-Based Medicine (Requires free registration)

195. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. (PubMed)

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone.In a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned 5170 patients within 24 hours after the onset of minor ischemic stroke (...) or high-risk TIA to combination therapy with clopidogrel and aspirin (clopidogrel at an initial dose of 300 mg, followed by 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days) or to placebo plus aspirin (75 mg per day for 90 days). All participants received open-label aspirin at a clinician-determined dose of 75 to 300 mg on day 1. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis. Treatment

2013 NEJM

196. Randomised controlled trial: Aspirin given for up to 2?years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding (Full text)

Randomised controlled trial: Aspirin given for up to 2?years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding Aspirin given for up to 2 years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your (...) cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin given for up to 2 years

2013 Evidence-Based Nursing PubMed

197. Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin

Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Article Text Aetiology Cohort study Lack

2013 Evidence-Based Medicine (Requires free registration)

198. Ischaemic stroke: sometimes thrombolysis and very often aspirin

Ischaemic stroke: sometimes thrombolysis and very often aspirin Prescrire IN ENGLISH - Spotlight ''Ischaemic stroke: sometimes thrombolysis and very often aspirin '', 1 November 2013 {1} {1} {1} | | > > > Ischaemic stroke: sometimes thrombolysis and very often aspirin Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Ischaemic stroke: sometimes (...) thrombolysis and very often aspirin In the acute phase of an ischaemic stroke, some patients benefit from thrombolysis when it is administered within 3 hours. Most patients are treated with aspirin. Some 80% of strokes are of ischaemic origin (blocked vessels). Around 12% of patients die within the three months following the stroke, and 20% remain in an institution or are highly dependent. When a person shows symptoms of a stroke, it is advisable to get them to hospital as quickly as possible so they can

2013 Prescrire

199. Vitamin E in Combination With Aspirin Can Pose Potential Postoperative Bleeding

Vitamin E in Combination With Aspirin Can Pose Potential Postoperative Bleeding UTCAT2440, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Vitamin E in Combination With Aspirin Can Pose Potential Postoperative Bleeding Clinical Question In a patient undergoing oral surgery, can vitamin E in combination with aspirin pose increased risk of postoperative bleeding? Clinical Bottom Line Both articles indicate the enhanced (...) anti-platelet effect of aspirin in combination with vitamin E. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Celestini/2002 Healthy Human (blood) taking no medication. In vitro study Key results The anti-platelet aggregation effect of acetylsalicylic acid was enhanced in presence of vitamin E, by increasing the NO(nitrous oxide) production 42 fold(P #2) Gonzalez-Correa/2005 Whole blood from healthy

2013 UTHSCSA Dental School CAT Library

200. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. (PubMed)

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding. We investigated the safety and efficacy of clopidogrel alone compared with clopidogrel (...) plus aspirin.We did an open-label, multicentre, randomised, controlled trial in 15 centres in Belgium and the Netherlands. From November, 2008, to November, 2011, adults receiving oral anticoagulants and undergoing PCI were assigned clopidogrel alone (double therapy) or clopidogrel plus aspirin (triple therapy). The primary outcome was any bleeding episode within 1 year of PCI, assessed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00769938.573 patients were

2013 Lancet